Partial
Mostly Aligned
Patient Risk:
Low
Summary
Some claims match label-supported indications/age groups, but multiple non-label claims are included (pricing/insurance/financial assistance and generic/biosimilar market dynamics). These cannot be verified against the supplied prescribing information excerpts, producing substantial unsupported content.
Category Scores
Accurate Statements
Dupixent is approved for the treatment of moderate-to-severe atopic dermatitis in patients aged six months and older.
Indications and Usage 1.1 Atopic Dermatitis: indicated for adult and pediatric patients aged 6 months and older with moderate-to-severe AD.
Dupixent is approved for the treatment of moderate-to-severe asthma in patients aged six years and older.
Indications and Usage 1.1/1.2 Asthma: indicated as add-on maintenance treatment of adult and pediatric patients aged 6 years and older.
Dupixent is approved as an add-on treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis.
Indications and Usage 1.5 (as reflected in provided label excerpts 2.5 dosing): chronic rhinosinusitis with nasal polyps indicated as appropriate add-on maintenance treatment; provided excerpt confirms dosing population 12 years and older, but add-on indication is not contradicted by supplied excerpts.
Unsupported Statements
Without insurance, the list price for a 30-day supply of Dupixent can range from approximately $3,500 to over $4,000.
No pricing/list price information is present in the supplied prescribing information excerpts.
The annual cost of Dupixent without insurance can exceed $40,000.
No pricing/cost information is present in the supplied prescribing information excerpts.
Insurance coverage for Dupixent often requires prior authorization to confirm medical necessity.
No payer/insurance prior authorization requirements are described in the supplied prescribing information excerpts.
Many insurance plans offer coverage for Dupixent, but copayments or coinsurance can still apply depending on the plan.
No information about copayments/coinsurance/coverage terms is present in the supplied prescribing information excerpts.
Patients may face out-of-pocket costs that differ from the list price.
No patient out-of-pocket cost information is present in the supplied prescribing information excerpts.
Sanofi offers patient assistance programs for Dupixent to help eligible individuals reduce out-of-pocket expenses.
No patient assistance program information is present in the supplied prescribing information excerpts.
Sanofi patient assistance programs can include copay cards that lower the amount patients pay per prescription.
No copay card/financial aid mechanism information is present in the supplied prescribing information excerpts.
Copay cards and other financial aid through the manufacturer may require patients to have commercial insurance and face high copay costs.
No financial aid eligibility/requirements/limitations are present in the supplied prescribing information excerpts.
Upon patent expiry, the market may see the introduction of generic or biosimilar versions of Dupixent.
No patent/generics/biosimilars market forecasting information is present in the supplied prescribing information excerpts.
The availability of generic or biosimilar alternatives typically leads to a significant reduction in the overall price of the medication.
No economic/market pricing impact information is present in the supplied prescribing information excerpts.
The timeline for when generic or biosimilar competitors can enter the market depends on specific patent expirations and any potential legal challenges.
No market entry timeline/legal challenge information is present in the supplied prescribing information excerpts.
Contradictions
Important Omissions
The response does not cite or summarize any label-supported dosing, contraindications, boxed warnings, or key warnings/precautions that would be necessary to substantiate safety-related or administration-related claims (though none were made in those areas).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated content includes mainly economic/coverage and market-dynamics statements plus some indication/age claims. It does not assert dosing, contraindications, or safety risks. Unsupported financial/market statements are unlikely to directly cause clinical harm based solely on the label excerpts provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple non-label claims (pricing, insurance requirements/coverage structure, patient assistance/coplay cards, and generic/biosimilar market dynamics) are not supported by the supplied FDA prescribing information excerpts.
Suggested Improvement
Remove or clearly qualify non-label pricing/coverage/assistance and generic/biosimilar market statements; limit claims to information present in the prescribing information excerpts (e.g., indications/age criteria, contraindications, dosing, and labeled warnings/precautions).